What is Maxim Bio?
Headquartered in Maryland, Maxim Bio operates as a specialized manufacturer of lateral flow and diagnostic devices. The company serves a diverse array of industries, ranging from food safety and veterinary diagnostics to infectious disease management and women's health. By providing precision turnkey development and manufacturing services, Maxim Bio acts as a vital partner for both private healthcare enterprises and government agencies. With a proven track record of delivering over 15 million tests globally, the company maintains strict adherence to FDA regulations and ISO standards, ensuring that its diagnostic solutions meet the highest benchmarks for quality and reliability in a competitive market landscape.
How much funding has Maxim Bio raised?
Maxim Bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Maxim Bio
PPP
Public-Private Partnership
What's next for Maxim Bio?
With the infusion of this late-stage capital, Maxim Bio is well-positioned to accelerate its innovation pipeline and expand its manufacturing footprint. The strategic focus will likely shift toward enhancing production throughput and diversifying its diagnostic portfolio to address emerging biodefense and public health challenges. As the company matures, the emphasis on maintaining high-compliance manufacturing processes will remain a cornerstone of its growth strategy, allowing it to capture additional market share in the rapidly evolving diagnostics industry. Future initiatives will likely involve scaling operations to support larger government contracts and deepening its integration within the global healthcare infrastructure.
See full Maxim Bio company page
